U.S. markets gained Friday after data showed more jobs were created in February than forecasted. The Dow Jones Industrial average gained 0.19 percent to close up 0.8 percent for the week, while the S&P 500 Index gained 0.05 percent to close up 1.0 percent for the week. On Friday, the Labor Department reported nonfarm payrolls increased by a seasonally adjusted 175,000 in February, topping the consensus estimate of 150,000. "It's a very encouraging report, indicating that we've mostly seen weather disruptions," said Morgan Stanley economist Ted Wieseman. Here is how some stocks reacted Friday:
Baxano Surgical Inc. (NASDAQ: BAXS) shares traded in the range of $1.38 to $1.58 Friday before settling to close at $1.49, a decrease of 11.41 percent. The stock appears to be facing some resistance at the $1.58 and $1.65 levels with some support at $1.45 and $1.43. The company reported a net loss of $0.19 per common share in the fourth quarter of 2013. Shares of Baxano Surgical have gained approximately 47.0 percent year-to-date.
More information on Baxano Surgical and access to the free equity report can be found at:
Burcon NutraScience Corp. (NASDAQ: BUR) shares traded in the range of $3.37 to $4.23 Friday before settling to close at $4.00, an increase of 22.70 percent. The stock appears to have some support at the $3.70, $3.51, and $3.38 levels. The company announced its intention to expand commercial production of CLARISOY. Shares of Burcon NutraScience have gained approximately 33.0 percent year-to-date.
More information on Burcon NutraScience and access to the free equity report can be found at:
Genocea Biosciences Inc. (NASDAQ: GNCA) shares traded in the range of $18.45 to $22.72 Friday before settling to close at $22.45, an increase of 23.28 percent. The stock appears to have some support at the $21.22, $16.56 and $15.54 levels. Cowen and Company have recently initiated coverage on the company with an “outperform” rating and a price target of $40.00. Shares of Genocea Biosciences have gained over 100.0 percent year-to-date.
More information on Genocea Biosciences and access to the free equity report can be found at:
TransAct Technologies Inc. (NASDAQ: TACT) shares traded in the range of $9.80 to $11.15 Friday before settling to close at $9.99, a decrease of 14.10 percent. The stock appears to be facing some resistance at the $14.78, $13.98 and $13.57 levels. The company reported net sales were $12.5 million for the fourth quarter of 2013, down from $19.6 million a year ago. Shares of TransAct Technologies have fallen approximately 20.0 percent year-to-date.
More information on TransAct Technologies and access to the free equity report can be found at:
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Wall Street Fundamentals
Email: [email protected]